Westfield Capital Management Co. LP Boosts Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Westfield Capital Management Co. LP lifted its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,133,766 shares of the biotechnology company's stock after acquiring an additional 170,942 shares during the quarter. Ascendis Pharma A/S accounts for approximately 3.5% of Westfield Capital Management Co. LP's portfolio, making the stock its 4th largest holding. Westfield Capital Management Co. LP owned about 8.47% of Ascendis Pharma A/S worth $766,523,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of ASND. Bessemer Group Inc. boosted its position in shares of Ascendis Pharma A/S by 61.0% in the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company's stock worth $132,000 after buying an additional 332 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company's stock valued at $269,374,000 after buying an additional 336,976 shares during the last quarter. Farallon Capital Management LLC bought a new stake in shares of Ascendis Pharma A/S during the 1st quarter valued at about $16,478,000. DNB Asset Management AS acquired a new stake in shares of Ascendis Pharma A/S in the 2nd quarter worth about $456,000. Finally, Harbor Capital Advisors Inc. boosted its position in Ascendis Pharma A/S by 137.2% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 52,200 shares of the biotechnology company's stock worth $7,119,000 after acquiring an additional 30,194 shares during the period.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ASND shares. Citigroup boosted their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a "buy" rating in a report on Tuesday, September 17th. Oppenheimer dropped their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a report on Friday, November 15th. JPMorgan Chase & Co. reduced their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an "overweight" rating for the company in a research note on Wednesday, October 23rd. Jefferies Financial Group boosted their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a "buy" rating in a report on Tuesday, August 13th. Finally, Wells Fargo & Company boosted their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an "overweight" rating in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat.com, Ascendis Pharma A/S currently has an average rating of "Moderate Buy" and an average price target of $191.77.

Ascendis Pharma A/S Stock Up 5.8 %

ASND stock traded up $7.17 during midday trading on Friday, reaching $129.81. The company's stock had a trading volume of 640,002 shares, compared to its average volume of 472,249. The business's 50-day simple moving average is $133.22 and its 200-day simple moving average is $132.19. The stock has a market cap of $7.87 billion, a PE ratio of -16.07 and a beta of 0.66. Ascendis Pharma A/S has a 52 week low of $90.13 and a 52 week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. As a group, equities analysts forecast that Ascendis Pharma A/S will post -7.45 earnings per share for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.